Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

A risk-adapted strategy based on all- trans retinoic acid (ATRA) and anthracycline monochemotherapy (PETHEMA LPA99 trial) has demonstrated a high antileukemic efficacy in acute promyelocytic leukemia. We designed a new trial (LPA2005) with the objective of achieving stepwise improvements in outcome. Between July 2005 and April 2009, low- and intermediate-risk patients (leukocytes as [NCT00408278][1]. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00408278&atom=%2Fbloodjournal%2F115%2F25%2F5137.atom